Surgery
Volume 134, Issue 4 , Pages 542-547 , October 2003

Cost-effectiveness of sentinel lymph node biopsy in thin melanomas

,Accepted 11 May 2003.

References 

  1. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C. Multi-institutional melanoma lymphatic mapping experience: the prognostic status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  2. Balch CM, Buzaid AC, Seng-Jaw S, Atkins MB, Cascinelli N, Coit DG, et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy in high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  4. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Niewig OE, et al.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg. 1999;230:453–463
  5. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol. 2000;7:160–165
  6. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumor thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg. 2002;89:1223–1227
  7. Nguyen CL, McClay EF, Cole DJ, O'Brien PH, Gillanders WE, Metcalf JS, et al.  Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001;181:8–11
  8. Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg. 1985;202:98–103
  9. Corsetti RL, Allen HM, Wanebo HJ. Thin ≤1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol. 2000;7:456–460
  10. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reitngen DS, Cascinelli N. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  11. Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg. 1987;122:1147–1150
  12. Guitart J, Lowe L, Peipkorn M, Prieto VG, Rabkin MS, Ronan SG, et al.  Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603–608
  13. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994;73:2324–2332
  14. Houghton AN, Bloomer WD, Chu D, Coit DG, Eisenberg BL, Guitart J, et al. The NCCN Melanoma Cancer clinical practice guidelines in oncology, version 1.2002. Available at: http://www.nccn.org/physician_gls/index.html. Accessed Jan 27, 2003. To view the most recent version of the guideline, go online to www.nccn.org.
  15. Albert VA, Koh HK, Bellar AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol. 1990;23:308–310
  16. Reintgen DS, Cox EB, McCarty KS, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg. 1983;198:379–385
  17. McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet. 1985;161:575–580
  18. Shen P, Guenther JM, Wanek LA, Morton DL. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?. Ann Surg Oncol. 2000;7:114–119
  19. McCarthy WH, Shaw HM, McCarthy SW, River JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol. 1996;23:709–713
  20. Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol. 2002;9:207–214
  21. Heyland DK, Gafni A, Kernerman P, Keenan S, Chalfin D. How to use the results of an economic evaluation. Crit Care Med. 1999;27:1195–1202
  22. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:93–109

☆ Presented at the 60th Annual Meeting of the Central Surgical Association, Toronto, Ontario, Canada, March 20–22, 2003.

PII: S0039-6060(03)00275-7

doi: 10.1016/S0039-6060(03)00275-7

Surgery
Volume 134, Issue 4 , Pages 542-547 , October 2003

Article Tools

* Image Usage & Resolution